Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05918406 · ClinicalTrials.gov registry record · Phase 4

Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya

A Phase 4 study, sponsored by Oyster Point Pharma.

Completed
Registry status
Phase 4
Development phase
30
Enrollment target

NCT05918406 is a Phase 4 study that has completed, run by Oyster Point Pharma. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05918406, a Phase 4 study, has completed, sponsored by Oyster Point Pharma.

COMPLETED
Registry status
Phase 4
Development phase
30 participants
Enrollment target

Study Summary

The objective of this study is to determine the safety of the nasal guide when utilized to aid in the administration of Tyrvaya (varenicline solution 0.03mg) Nasal Spray

Interventions

  • COMBINATION_PRODUCT Nasal Guide

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-06-14
Est. Completion 2023-08-18
Phase Phase 4

Sponsor

Oyster Point Pharma

10 total trials

What the Registry Record Tells You About NCT05918406

The ClinicalTrials.gov registry entry for NCT05918406 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oyster Point Pharma, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Nasal Guide is the first listed.

NCT05918406 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05918406 about?

NCT05918406 is a clinical study titled "Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya". The objective of this study is to determine the safety of the nasal guide when utilized to aid in the administration of Tyrvaya (varenicline solution 0.03mg) Nasal Spray

What is the current status of trial NCT05918406?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2023-06-14. Estimated completion is 2023-08-18.

What interventions are being tested in trial NCT05918406?

The interventions under investigation include: Nasal Guide (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT05918406?

This trial is sponsored by Oyster Point Pharma, which has 10 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.